Minerva Neurosciences (NERV) Common Equity (2013 - 2026)
Minerva Neurosciences posted quarterly Common Equity of -$254.0 million for Q1 2026, down 771.44% year-on-year from $37.8 million in Q1 2025, and down 80.47% on a QoQ basis from -$140.7 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Common Equity data on file, last reported at -$254.0 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity fell 771.44% year-over-year to -$254.0 million; the trailing twelve-month figure through Mar 2026 stood at -$254.0 million (down 771.44% YoY), and the FY2025 full-year result was -$140.7 million, down 447.8% from the prior year.
- Common Equity for Q1 2026 stood at -$254.0 million, down from -$140.7 million in the prior quarter.
- Across five years, Common Equity topped out at -$736130.0 in Q1 2022 and bottomed at -$254.0 million in Q1 2026.
- The 5-year median for Common Equity is -$26.6 million (2023), against an average of -$44.1 million.
- The widest annual swing landed in 2023, when Common Equity tumbled 3515.96%; it then grew 27.83% in 2025.
- A 5-year view of Common Equity shows it stood at -$20.0 million in 2022, then tumbled by 42.12% to -$28.5 million in 2023, then grew by 9.71% to -$25.7 million in 2024, then tumbled by 447.8% to -$140.7 million in 2025, then slumped by 80.47% to -$254.0 million in 2026.
- The last three Common Equity figures came in at -$254.0 million (Q1 2026), -$140.7 million (Q4 2025), and -$34.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -254.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -254.01 Mn |
| Dec 31, 2025 | -140.75 Mn |
| Sep 30, 2025 | -34.58 Mn |
| Jun 30, 2025 | -32.11 Mn |
| Mar 31, 2025 | -29.15 Mn |
| Dec 31, 2024 | -25.69 Mn |
| Sep 30, 2024 | -21.67 Mn |
| Jun 30, 2024 | -44.49 Mn |
| Mar 31, 2024 | -36.59 Mn |
| Dec 31, 2023 | -28.46 Mn |
| Sep 30, 2023 | -20.05 Mn |
| Jun 30, 2023 | -12.51 Mn |
| Mar 31, 2023 | -26.62 Mn |
| Dec 31, 2022 | -20.02 Mn |
| Sep 30, 2022 | -14.25 Mn |
| Jun 30, 2022 | -8.38 Mn |
| Mar 31, 2022 | -736,130.00 |
| Dec 31, 2021 | 7.98 Mn |
| Sep 30, 2021 | 28.08 Mn |
| Jun 30, 2021 | 36.17 Mn |
| Mar 31, 2021 | 45.37 Mn |
| Dec 31, 2020 | 52.66 Mn |
| Sep 30, 2020 | 58.02 Mn |
| Jun 30, 2020 | 56.94 Mn |
| Mar 31, 2020 | 18.62 Mn |
| Dec 31, 2019 | 27.78 Mn |
| Sep 30, 2019 | 55.53 Mn |
| Jun 30, 2019 | 67.27 Mn |
| Mar 31, 2019 | 77.42 Mn |
| Dec 31, 2018 | 90.26 Mn |
| Sep 30, 2018 | 101.39 Mn |
| Jun 30, 2018 | 110.66 Mn |
| Mar 31, 2018 | 121.29 Mn |
| Dec 31, 2017 | 131.60 Mn |
| Sep 30, 2017 | 130.18 Mn |
| Jun 30, 2017 | 98.03 Mn |
| Mar 31, 2017 | 106.29 Mn |
| Dec 31, 2016 | 105.98 Mn |
| Sep 30, 2016 | 113.14 Mn |
| Jun 30, 2016 | 120.61 Mn |
| Mar 31, 2016 | 66.65 Mn |
| Dec 31, 2015 | 55.32 Mn |
| Sep 30, 2015 | 63.07 Mn |
| Jun 30, 2015 | 68.38 Mn |
| Mar 31, 2015 | 74.44 Mn |
| Dec 31, 2014 | 51.50 Mn |
| Sep 30, 2014 | 56.72 Mn |
| Jun 30, 2014 | 29.23 Mn |
| Dec 31, 2013 | 20.18 Mn |